Equity Overview
Price & Market Data
Price: $0.613
Daily Change: -$0.048 / 7.83%
Daily Range: $0.599 - $0.70
Market Cap: $13,092,098
Daily Volume: 217,145
Performance Metrics
1 Week: -10.06%
1 Month: -50.08%
3 Months: -51.26%
6 Months: -94.55%
1 Year: -94.19%
YTD: -94.63%
Company Details
Employees: 5
Sector: Health technology
Industry: Biotechnology
Country:
Details
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma that is in phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.